Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Narrows Q2 Loss 62 Percent Though Revenue Slides 10 Percent

NEW YORK (GenomeWeb News) – Transgenomic today said that total revenue declined 10 percent in the second quarter and net loss narrowed 62 percent.
 
Receipts for the second quarter ended June 30 slid to $6.2 million from $6.9 million in the same quarter last year.
 
The company spent about $531,000 on R&D in the second quarter, down 9 percent from $581,000 in the comparable period last year.
 
Transgenomic said net loss shrank to $383,000 from $998,000 in Q2 2005.
 
As of June 30, Transgenomic had approximately $7.4 million in cash and cash equivalents.
 

Looking ahead, Craig Tuttle, Transgenomic’s president and CEO, said in a statement that his “immediate priorities” are to “maximize opportunities from existing products, focus and streamline the product development pipeline, and to accelerate the drive to profitability.”

“We are currently looking to commercialize several new products and services that leverage on enhancing the capabilities of our highly sensitive and effective mutation screening technologies,” he said. 

The first of these is Transgenomic’s Surveyor CE technology, which is designed to reduce the cost and time required for discovering mutations using routine sequencing platforms. 

The second is a “stronger commercial push” of the company’s lab services business both for research and clinical discovery of disease-causing mutations, he said. 

The third is based on Transgenomic’s capabilities for isolating DNA from mixed specimens for forensic and microbial analyses. He said the company saw “growing success” in its cytogenetics product portfolio.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.